ArticleACS omega2026
Efficient Synthesis of Novel Propargyl Sulfamate Derivatives and Their Potent Inhibitory Effects on Human Carbonic Anhydrase Isoenzymes.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the present study, a total of 21 novel propargyl sulfamate derivatives were designed and synthesized as potential inhibitors of human carbonic anhydrases I and II (hCA I and hCA II). An efficient and practical synthetic protocol was developed based on the reaction of propargyl alcohols with chlorosulfonyl isocyanate (CSI), affording the target sulfamate compounds in good yield. The inhibitory activities of all synthesized compounds against hCA I and hCA II isoenzymes were evaluated in vitro. The compounds exhibited potent inhibition with IC
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.